Ana Regina de Abreu, Ayla Wyninckx, Timon Vandamme, Ken Op de Beeck, Guy Van Camp, Marc Peeters, Pierre Laurent-Puig, Julien Taieb, Valerie Taly, Leonor Benhaim
{"title":"ctDNA Detection in Cancer: A Comprehensive Overview of Current Detection Methods and Prospects.","authors":"Ana Regina de Abreu, Ayla Wyninckx, Timon Vandamme, Ken Op de Beeck, Guy Van Camp, Marc Peeters, Pierre Laurent-Puig, Julien Taieb, Valerie Taly, Leonor Benhaim","doi":"10.1093/oncolo/oyaf204","DOIUrl":null,"url":null,"abstract":"<p><p>The analysis of circulating tumor DNA (ctDNA) has emerged as a major minimally invasive biomarker in oncology. Numerous methods exist for ctDNA detection and should be selected based on the specific oncological context. PCR-based methods are often preferred for their sensitivity and cost-effectiveness; however, they are limited to a narrower range of genes. In contrast, NGS-based methods enable comprehensive cancer genotyping and more efficient identification of actionable mutations. Moreover, the growing number of emerging approaches, such as third-generation sequencing and fragmentomics, highlights the increasing technical complexity of ctDNA detection. Overall, this review provides insights into the advantages and limitations of various detection strategies that can help improve clinical care for patients.</p>","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":" ","pages":""},"PeriodicalIF":4.8000,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncologist","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/oncolo/oyaf204","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
The analysis of circulating tumor DNA (ctDNA) has emerged as a major minimally invasive biomarker in oncology. Numerous methods exist for ctDNA detection and should be selected based on the specific oncological context. PCR-based methods are often preferred for their sensitivity and cost-effectiveness; however, they are limited to a narrower range of genes. In contrast, NGS-based methods enable comprehensive cancer genotyping and more efficient identification of actionable mutations. Moreover, the growing number of emerging approaches, such as third-generation sequencing and fragmentomics, highlights the increasing technical complexity of ctDNA detection. Overall, this review provides insights into the advantages and limitations of various detection strategies that can help improve clinical care for patients.
期刊介绍：
The Oncologist® is dedicated to translating the latest research developments into the best multidimensional care for cancer patients. Thus, The Oncologist is committed to helping physicians excel in this ever-expanding environment through the publication of timely reviews, original studies, and commentaries on important developments. We believe that the practice of oncology requires both an understanding of a range of disciplines encompassing basic science related to cancer, translational research, and clinical practice, but also the socioeconomic and psychosocial factors that determine access to care and quality of life and function following cancer treatment.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
